InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,722.26
(
-0.19%
)
US TECH 100
19,517.20
(
0.53%
)
Dow Jones
41,914.75
(
-0.70%
)
Brent Oil
73.18
(
-0.02%
)
Bitcoin
63,173.88
(
0.06%
)
Post# of 253225
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120502
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ronpopeil post# 223241

Friday, 01/18/2019 6:07:26 AM

Friday, January 18, 2019 6:07:26 AM

Post# of 253225
IMMU CRL based on CMC issues only (according to the company):

http://globenewswire.com/news-release/2019/01/18/1701746/0/en/Immunomedics-Receives-Complete-Response-Letter-From-FDA-for-Sacituzumab-Govitecan-Biologics-License-Application.html

The issues related to approvability in the CRL were exclusively focused on Chemistry, Manufacturing and Control matters and no new clinical or preclinical data need to be generated.

CC at 8am ET.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up